Compare WIMI & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WIMI | MRKR |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.2M | 18.7M |
| IPO Year | 2019 | 2010 |
| Metric | WIMI | MRKR |
|---|---|---|
| Price | $1.03 | $1.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 100.2K | 84.0K |
| Earning Date | 04-24-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.61 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $936.27 |
| P/E Ratio | $1.24 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.07 | $0.84 |
| 52 Week High | $5.65 | $2.46 |
| Indicator | WIMI | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | 27.67 | 44.33 |
| Support Level | N/A | $1.10 |
| Resistance Level | $1.43 | $1.36 |
| Average True Range (ATR) | 0.08 | 0.12 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 0.00 | 4.76 |
WiMi Hologram Cloud Inc and its subsidiaries offer augmented reality (AR) based holographic services and products to cater to its customers. Its AR service and product offerings consist of holographic AR advertising services and holographic AR entertainment products. It is also into the semiconductor business, in which the company provides central processing algorithm services and computer chip products to enterprise customers and the sales of comprehensive solutions for central processing algorithms and related services with software and hardware integration. The company reports in three segments: AR advertising, AR entertainment, and Semiconductor. Its geographical segments are Mainland China, Hong Kong, and International.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).